flu vaccine news from FierceBiotech
NewsEmergent adds new space for biotech start-ups
Emergent Technologies Inc has doubled its office space, taking new digs in Austin that includes new laboratory space for the biotech companies that it helps foster. ETI specializes in creating new Read more...
Novartis eyes vaccines with Protez purchase
Novartis is shelling out $400 million for antibiotics developer Protez Pharmaceuticals. Protez gets for $100 million up front and up to $300 million more if Protez's new broad-spectrum antibiotic is Read more...
Emergent BioSolutions buys flu vaccine maker
Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent's strategy to expand its product portfolio with a drug Read more...
GSK bird flu vaccine wins race for European OK
After investing about $2 billion in development efforts, GlaxoSmithKline has won European approval for the first bird flu vaccine that can be used either in advance of or in the early days of a human Read more...
ALSO NOTED: GSK releases new Cervarix data; FDA mulls DTC ads; and much more...
> GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of Read more...
ALSO NOTED: Genentech options Exelixis inhibitor; Millennium reports positive data for cancer cocktail; Immtech CEO takes a pay
> Exelixis announced that Genentech has exercised an option to develop Exelixis' XL518, a selective inhibitor of MEK which is currently in a Phase I clinical trial. Exelixis earns $3 million on Read more...
Novartis ends cancer trial early after hitting endpoint
Novartis has brought a late-stage study of its kidney cancer drug everolimus to a premature close after an independent review committee determined the therapy had extended patients' lives without Read more...
Novartis established nonprofit vaccine institute
Novartis has established the Novartis Vaccines Institute for Global Health, a nonprofit venture that will take aim at diseases in the developing world. The NVGH, which will be separate from Novartis' Read more...
SPOTLIGHT: Gates backs new vaccine technology
PATH is using a $39 million grant from the Gates Foundation to help developing countries identify ways to manufacture and stockpile vaccines that could be used to defend their populations against an Read more...
ALSO NOTED: Phyton cuts staff; Alzheimer's: A new indication for Enbrel?; and much more...
> According to research released today, the anti-rheumatoid arthritis med Enbrel has shown an amazing ability to rehabilitate Alzheimer's patients. Read more...
| Press ReleasesAcambis reports positive data from trials of universal influenza A vaccine Acambis reports positive data from trials of universal influenza A vaccine Cambridge, UK and Cambridge, Massachusetts – 3 January 2008 – Acambis plc (Acambis) (LSE: ACM), a leading vaccine Read more... PRESS RELEASE: VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine Company’s First Clinical Trial Studies Vaccine Based on New Vaccine Technology Cranbury, NJ, September 25, 2007 – Read more... PRESS RELEASE: Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine SWIFTWATER, Pa., and LYON, France, Nov. 7 -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, Read more... |
Get more flu vaccine coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets